Zejula

Zejula (niraparib) is an oral prescription medicine used for ovarian cancer maintenance therapy. It belongs to the PARP inhibitor class, designed to help prevent cancer recurrence. Suitable for adults with platinum-sensitive recurrent disease. Always consult a healthcare provider for suitability.

Zejula (niraparib) is prescribed to help maintain remission in adults with ovarian cancer after platinum-based chemotherapy. It is used for patients with recurrent disease that has responded to platinum therapy. The medication works by targeting cancer cells to delay progression. It is not intended for first-line treatment.

Zejula may help reduce the risk of cancer progression by interfering with cancer cell repair mechanisms. Some users report mild fatigue or digestive changes during treatment. Individual responses vary, and effects are typically monitored by a healthcare professional. Regular check-ups are recommended to assess progress.

Zejula should be taken exactly as prescribed by a healthcare provider. Keep out of reach of children and store at room temperature. Inform your doctor about all medications and conditions before starting treatment. Blood tests may be required to monitor safety during therapy.

Zejula may interact with other medications, including strong CYP3A inhibitors or inducers. Avoid grapefruit products while taking this medicine. Certain blood pressure or seizure medications may also affect how Zejula works. Always discuss current medications with your healthcare provider.